Table 4 Sample prevalence rates for Gen1 and Gen2 for male and female participants, %, 95% CIs
Prevalence period (shoulder pain type) | sample % | 95% CI | Male % | 95% CI | Female % | 95% CI |
|---|---|---|---|---|---|---|
Gen1 | ||||||
SP 1-month | 34.2 | 31.3–37.0 | 31.8 | 27.5–36.2 | 35.8 | 32.0-39.7 |
SP 1-month (UL) | 21.8 | 19.2–24.1 | 19.9 | 16.1–23.7 | 23.1 | 19.6–26.4 |
SP 1-month (BL) | 12.4 | 10.2–14.4 | 11.9 | 9.3–14.9 | 12.7 | 10.3–15.5 |
Gen2 | ||||||
SP point | 11.4 | 9.8–13.3 | 7.7* | 5.4–10.0 | 14.7* | 11.0-17.8 |
SP point (UL) | 6.3 | 4.9–7.7 | 5.8 | 3.9–7.9 | 6.7 | 4.8–8.6 |
SP point (BL) | 5.1 | 3.9–6.5 | 1.9* | 0.9–3.1 | 8.0* | 5.9–10.5 |